Search Results - marcus+horwitz

5 Results

Sort By:

Novel Safe Potent Single Vector Platform Vaccines Against Melioidosis (UCLA Case No. 2023-119)

UCLA researchers in the School of Medicine have developed a novel single-vector platform vaccine for preventing melioidosis, an infection caused by Burkholderia pseudomallei. BACKGROUND: Melioidosis, also known as Whitmore’s disease, is an infectious disease that can infect both humans and animals. The bacterium Burkholderia pseudomallei (Bp)...

Published: 2/21/2024 | Inventor(s): Marcus Horwitz

Keywords(s): Burkholderia pseudomallei, Intracellular Pathogens, Live attenuated vaccine, Melioidosis, Pathogen, Select Agents, Tier 1 Diseases, Vaccines

Category(s): Therapeutics > Infectious Diseases

2022-197 Novel Live Multi-Antigenic Recombinant Vaccine Against Tuberculosis

SUMMARY: Researchers at UCLA’s School of Medicine have developed a potent multi-antigen vaccine for protection against tuberculosis. BACKGROUND: Tuberculosis (TB) is an infectious disease that, when active, can affect many organs in the body but can especially cause severe lung disease manifest by chronic cough, fever, and weight loss, and, if...

Published: 2/23/2024 | Inventor(s): Marcus Horwitz

Keywords(s):

Category(s): Therapeutics, Therapeutics > Inflammation And Inflammatory Diseases, Therapeutics > Vaccines

2020-871 SAFE POTENT SINGLE VECTOR PLATFORM VACCINE AGAINST COVID-19

UCLA researchers in the Department of Medicine have utilized a highly attenuated replicating bacterial vector platform to develop a vaccine against SARS-CoV-2 in humans and animals to prevent COVID-19. BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), closely related to SARS-CoV, is an enveloped, single-stranded positive RNA...

Published: 2/29/2024 | Inventor(s): Marcus Horwitz

Keywords(s): Infectious Diseases, Therapeutics & Vaccines, Vaccines, Viral Delivery Systems

Category(s): Therapeutics > Vaccines, Therapeutics > Infectious Diseases, Therapeutics > Infectious Diseases > COVID

2016-992 SAFE POTENT SINGLE PLATFORM VACCINE AGAINST TIER1 SELECT AGENTS AND OTHER PATHOGENS

SUMMARYUCLA researchers in the Department of Medicine have developed a novel vaccine platform against Tier 1 Select Agents to prevent infectious diseases such as tularemia, anthrax, plague, and melioidosis.BACKGROUNDTier 1 Select Agents are infectious agents that pose a severe threat to the public and can cause diseases such as tularemia, anthrax, plague...

Published: 2/29/2024 | Inventor(s): Marcus Horwitz, Qingmei Jia

Keywords(s): Infectious Diseases, Therapeutics & Vaccines

Category(s): Therapeutics, Therapeutics > Infectious Diseases

2017-840 NANOPARTICLES FOR SPECIFIC DETECTION AND KILLING OF PATHOGENIC BACTERIA

SummaryUCLA researchers in the Department of Chemistry and Biochemistry and Department of Medicine have developed novel functionalized mesoporous silica nanoparticles that can specifically identify pathogenic bacteria and deliver on-target drug treatments.BackgroundBacterial infection is a common illness that affects many Americans each year. The specific...

Published: 7/19/2023 | Inventor(s): Marcus Horwitz, Jeffrey Zink, Daniel Clemens, Bai-Yu Lee Clemens, Bastian Ruehle

Keywords(s): Chemical Manufacturing & Industrial/Bulk Chemicals, Drug Delivery, Infectious Diseases, Nanoparticles, Therapeutics & Vaccines

Category(s): Platforms > Drug Delivery, Therapeutics, Therapeutics > Infectious Diseases, Platforms > Drug Delivery > Nanoparticles, Chemical > Industrial & Bulk Chemicals